CLINICAL TRIALS PROFILE FOR TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00133692 ↗ | INVEST: INternational VErapamil SR Trandolapril STudy | Completed | Abbott | Phase 4 | 1997-09-01 | Because blood pressure affects the heart, blood vessels, kidneys, and the entire body, it is important to keep it as normal as possible. There are several different ways to control blood pressure and to prevent or limit the development of heart disease due to high blood pressure. The purpose of this study is to compare two treatments to see how well they work and the difference in their side effects. One treatment includes the use of a calcium antagonist drug (Isoptin sustained release [SR] or Verapamil SR). The other treatment excludes the calcium antagonist and may include a non-calcium antagonist drug called a beta blocker (Tenormin or Atenolol). Both treatments may also include medication called angiotensin converting enzyme (ACE) inhibitors and water pills. None of the drugs in this study are experimental, they are all approved by the Food and Drug Administration (FDA). |
| NCT00133692 ↗ | INVEST: INternational VErapamil SR Trandolapril STudy | Completed | University of Florida | Phase 4 | 1997-09-01 | Because blood pressure affects the heart, blood vessels, kidneys, and the entire body, it is important to keep it as normal as possible. There are several different ways to control blood pressure and to prevent or limit the development of heart disease due to high blood pressure. The purpose of this study is to compare two treatments to see how well they work and the difference in their side effects. One treatment includes the use of a calcium antagonist drug (Isoptin sustained release [SR] or Verapamil SR). The other treatment excludes the calcium antagonist and may include a non-calcium antagonist drug called a beta blocker (Tenormin or Atenolol). Both treatments may also include medication called angiotensin converting enzyme (ACE) inhibitors and water pills. None of the drugs in this study are experimental, they are all approved by the Food and Drug Administration (FDA). |
| NCT00234871 ↗ | Tarka® vs. Lotrel® in Hypertensive, Diabetic Subjects With Renal Disease (TANDEM) | Completed | Abbott | Phase 4 | 2004-01-01 | The primary objective of this study is to determine if trandolapril/verapamil (Tarka®) is superior to amlodipine/benazepril (Lotrel®) in reduction of albuminuria in hypertensive subjects with Type 2 diabetes mellitus (DM) and diabetic nephropathy |
| NCT00497666 ↗ | Association Between Rosiglitazone Use and Clinical Course of Diabetic Nephropathy: Population-Based Study | Unknown status | Assaf-Harofeh Medical Center | 2007-08-01 | Recent data show that Rosiglitazone treatment can reduce proteinuria in diabetic patients. However, currently there are no trials that examine the effects of Rosiglitazone on kidney disease progression, that is, doubling of serum creatinine or time to onset of end-stage renal disease, in patients with diabetic nephropathy. We decided to study retrospectively the possible association between rosiglitazone use and clinical course of diabetic nephropathy, including rate of deterioration of renal function, appearance and progression of microalbuminuria/proteinuria, survival and acceptance to renal replacement therapy. | |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE
Condition Name
Clinical Trial Locations for TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE
Trials by Country
Clinical Trial Progress for TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE
Clinical Trial Phase
Clinical Trial Sponsors for TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE
Sponsor Name
